GSK’s gepotidacin, a drug recently approved by the FDA for the management of uncomplicated urinary tract infections, has shown powerful efficacy against gonorrhea, a common sexually transmitted infection (STI). Recent findings published in The Lancet revealed that gepotidacin’s success rate in eradicating this infection slightly outpaced standard treatment methodologies.
Notably, the phase 3 study, called EAGLE-1, demonstrated effectiveness rates of 92.6% in the gepotidacin group and 91.2% in the ceftriaxone plus azithromycin group, clearly showing gepotidacin’s non-inferiority. Even though the gepotidacin group witnessed higher rates of mild to moderate adverse events, mainly related to the gastrointestinal system, there were no serious treatment-related adverse events reported in either group.
The randomized EAGLE-1 trial compared oral gepotidacin’s efficacy and safety with the standard treatment of 500mg intramuscular ceftriaxone plus 1g oral azithromycin. The participants, who had a bodyweight of over 45kg, a suspected uncomplicated urogenital gonorrhea, a positive laboratory test for Neisseria gonorrhoeae, or both, were randomly allocated in a 1:1 ratio to each treatment group, divided according to sex and sexual orientation. The primary efficacy endpoint was the eradication of gonorrhea at the test-of-cure stage (days 4–8) and assessed in the microbiological intention-to-treat population.
In 2023, confirmed gonorrhea cases reached 601,319 in the U.S, showing a minor 5-year decrease of 2.4%. Globally, according to the World Health Organization (WHO), the cases crossed the alarming mark of 82.4 million in 2020, making gonorrhea the second most prevalent STI after chlamydia.
In addition to the EAGLE-1 study, data from phase 3 trials EAGLE-2 and EAGLE-3, which led to gepotidacin’s initial FDA approval, showed non-inferiority to nitrofurantoin, a common treatment for uncomplicated urinary tract infections. As for adverse events, gastrointestinal issues were the most commonly reported complications in patients using gepotidacin, with diarrhea being the most frequent complaint.
These groundbreaking developments mark an important step in gonorrhea treatment and prevention. GSK is planning to seek FDA approval for gepotidacin as a treatment for gonorrhea later this year, opening potentially new avenues for the effective management of this widespread STI.